ICON plc | Clinical Research Organisation (CRO) for Drug Development

Medical communications in early phase product development

A step-by-step guide to creating market success.

Long-term follow-up studies of cell and gene therapies

Success factors related to conducting basket LTFU studies.

wearables smart watch connected for digital health technologies

Closing the evidence gap

The value of digital health technologies in supporting drug reimbursement decisions

Biotech and early engagement considerations

Navigate the complexities of developing an asset and considering a drug development partner.

Webinars

Webinar: Pharmacovigilance & patient safety

Access the webinar recording.

Webinar: ICON’s world children’s day

Access the webinar recording.

On-demand webinars

Visit our webinar channel to access other recent webinars.

Featured Services

Seeking parallel consultation from regulators and HTA bodies in Europe

Market Access

Expertise in mission-critical pricing, market access, and reimbursement.�

Site & Patient Solutions

Transforming recruitment through patient-centric trials and real-world, real-time data.

Biotech

ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.

Functional Resourcing

From recruitment of a single clinical professional to managing entire global functions.

Increasing Site and Patient Compliance

FIRECREST: Digital solutions to increase efficiency in clinical trials by driving site performance.

ICON Insights

07 December 2021

Camaraderie and collaboration – what sets ICON apart

ICON was recently named one of the World’s Best Employers for 2021 by global media company Forbes. This recognition is solely the result of employees’ on-the-job experiences and firsthand feedback.

10 November 2021

EC proposes extended transition period for IVDR compliance

The European Commission has issued a proposal for a modified rollout of the new In Vitro Diagnostic Regulation (IVDR).

01 November 2021

Diverse clinical research starts with the healthcare workforce

Diversity initiatives are a hallmark of clinical research. From US Food and Drug Administration (FDA)-penned guidance and pharma initiatives.

31 October 2021

How we can continue building a diverse, equal, and inclusive industry

Workplace diversity encourages collaboration and innovation – every team member brings their own unique backgrounds, experiences, and perspectives at ICON.

26 October 2021

Navigating cardiovascular clinical trial adjudication during a respiratory pandemic

COVID-19 disrupted clinical trials across all indications. Patient enrolment, participation, data collection, and more was forced to adapt to the challenges of this virus.

19 October 2021

The impact of the COVID-19 pandemic on mental health

Learn how the ongoing state of the COVID-19 pandemic has affected the global mental health crisis.

01 October 2021

ICON Joins UNICEF Corporate Vaccine Alliance

ICON is one of seven leading Irish companies that just endorsed an open letter urging fellow corporate leaders to join the UNICEF Corporate Vaccine Alliance.

20 September 2021

Rare disease patients and advocates drive change in public policy

Learn how patient advocacy organisations and rare disease communities are driving change in US public policy to make safe and effective treatment options available to all patients.

19 August 2021

The promise of glycomics in medicine

Glycomics has been a largely overlooked area of study. Nevertheless, it has the potential to have a significant impact on precision medicine and healthcare as a whole.

Services

Sectors

Therapeutics

Innovation

Insights

News & Events

About ICON

Understanding the Periodic Benefit-Risk Evaluation Report

Spotlight on regulatory reforms in China

Diversity and inclusion in clinical trials

Practical considerations for decentralised & hybrid clinical trials